Literature DB >> 9443167

Synthetic oligonucleotides: useful molecules? A review.

A Calogero1, G A Hospers, N H Mulder.   

Abstract

Specific inhibition of mammalian genes is possible through the use of antisense oligonucleotides (AS ODNs) or ribozymes. These strategies have led to a better understanding of several cellular and molecular mechanisms, among which cancer development. Recently, these strategies have been applied also for therapeutical purposes in diseases such as AIDS and cancer. In some of these therapeutical trials the antisense strategy is combined with gene transfer technology: the AS ODN or the ribozyme are expressed within the cell by the use of adenoviral or retroviral vectors. However, many difficulties have still to be overcome before ODNs and ribozymes can be used routinely in the clinic.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9443167     DOI: 10.1023/a:1008699515124

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  18 in total

1.  Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice.

Authors:  M F Neurath; S Pettersson; K H Meyer zum Büschenfelde; W Strober
Journal:  Nat Med       Date:  1996-09       Impact factor: 53.440

2.  Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.

Authors:  M Y Chiang; H Chan; M A Zounes; S M Freier; W F Lima; C F Bennett
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

Review 3.  Progress in antisense therapeutics.

Authors:  S T Crooke
Journal:  Hematol Pathol       Date:  1995

4.  Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus.

Authors:  D S Pisetsky; C F Reich
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

5.  Inhibition of transcription of HIV-1 in infected human cells by oligodeoxynucleotides designed to form DNA triple helices.

Authors:  W M McShan; R D Rossen; A H Laughter; J Trial; D J Kessler; J G Zendegui; M E Hogan; F M Orson
Journal:  J Biol Chem       Date:  1992-03-15       Impact factor: 5.157

6.  Cloning and functional characterization through antisense mapping of a kappa 3-related opioid receptor.

Authors:  Y X Pan; J Cheng; J Xu; G Rossi; E Jacobson; J Ryan-Moro; A I Brooks; G E Dean; K M Standifer; G W Pasternak
Journal:  Mol Pharmacol       Date:  1995-06       Impact factor: 4.436

Review 7.  Immunomodulation by cytokine antisense oligonucleotides.

Authors:  C Lefebvre d'Hellencourt; L Diaw; M Guenounou
Journal:  Eur Cytokine Netw       Date:  1995 Jan-Feb       Impact factor: 2.737

Review 8.  Gene replacement strategies for cancer.

Authors:  J A Roth
Journal:  Isr J Med Sci       Date:  1996-02

9.  Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.

Authors:  C Leonetti; I D'Agnano; F Lozupone; A Valentini; T Geiser; G Zon; B Calabretta; C Citro G; G Zupi
Journal:  J Natl Cancer Inst       Date:  1996-04-03       Impact factor: 13.506

10.  Oligonucleotide sequences required for natural killer cell activation.

Authors:  E Kuramoto; O Yano; Y Kimura; M Baba; T Makino; S Yamamoto; T Yamamoto; T Kataoka; T Tokunaga
Journal:  Jpn J Cancer Res       Date:  1992-11
View more
  4 in total

1.  Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.

Authors:  J B Opalinska; A Kalota; Lida K Gifford; Ponzy Lu; Kuang-Yu Jen; P I Pradeepkumar; J Barman; T K Kim; C R Swider; J Chattopadhyaya; A M Gewirtz
Journal:  Nucleic Acids Res       Date:  2004-10-28       Impact factor: 16.971

2.  Design of antisense oligonucleotides stabilized by locked nucleic acids.

Authors:  Jens Kurreck; Eliza Wyszko; Clemens Gillen; Volker A Erdmann
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

Review 3.  Novel translational strategies in colorectal cancer research.

Authors:  Ignacio Gil-Bazo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 4.  Applications of Ruthenium Complexes Covalently Linked to Nucleic Acid Derivatives.

Authors:  Marie Flamme; Emma Clarke; Gilles Gasser; Marcel Hollenstein
Journal:  Molecules       Date:  2018-06-22       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.